All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
23 results for "Cancer" and "Thoracic Cancers"
Phase I, First In Human Trial Evaluating BI 1387446 Alone And In Combination with BI 754091 in Solid Tumors
To characterize the safety and to determine the maximum tolerated dose (MTD) for BI 1387446 in combination with ezabenlimab (BI 754091).
Protocol No
BI-1426-0001
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients, NCCAPS Study. How does COVID19 affect the outcomes of people undergoing cancer treatment? How does having cancer affect COVID-19?
Protocol No
NCI-COVID-NCCAPS
A Phase 1 Dose Escalation Study to Assess Safety and Efficacy of ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
Protocol No
ADP-0055-001-MAGE-A4-SURPASS
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Testing the addition of radiation therapy to the usual immune therapy treatment (atezolizumab) for patients with extensive stage small cell lung cancer
Protocol No
NRG-LU007
Sub Category
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial PLATFORM TRIAL
This study will evaluate the efficacy and safety of multiple therapies that are selected
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
Protocol No
HOFFMANN-BO41932-TAPISTRY
Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
Protocol No
NRG-LU002
Sub Category
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Protocol No
ECOG-ALCHEMIST-E4512
Sub Category
Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Testing the addition of bevacizumab to AZD9291 (osimertinib) as a first-treatment for patients with EGFR-mutant lung cancer that has metastasized
Protocol No
ECOG-EA5182
Sub Category
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis
Improving the Treatment of Immunotherapy-related Lung Inflammation in Patients where Corticosteroids are No Longer Effective
Protocol No
ECOG-EAQ172
Sub Category
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated,NS-NSCLC
Protocol No
CALITHERA-CX-839-014-KEAPSAKE
Sub Category
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Testing the effects of MK-3475 (pembrolizumab) with or without the usual chemotherapy treatment for patients 70 years of age and older with advanced non-small cell lung cancer
Protocol No
ALLIANCE-A171901
Sub Category
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer
Durvalumab Following SBRT for the Treatment of Patients with Stage I/II NSCLC
Protocol No
AZ-D9103C00001-PACIFIC-4
Sub Category
Randomized, open label Phase 3 study of SAR408701 versus Docetaxel in previously treated metastatic non-squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors
Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic Non-Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors (CARMEN-LC03)
Protocol No
SANOFI-EFC15858
Sub Category
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Testing the Addition of an Antibody toStandard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients
With Unresectable Stage III Non-Small Cell Lung Cancer
With Unresectable Stage III Non-Small Cell Lung Cancer
Protocol No
ECOG-EA5181
Sub Category
Establishment Of A National Biorepository To Advance Studies Of Immune-Related Adverse Events
Collection of research data and samples from patients who experience immunotherapy side effects
Protocol No
ALLIANCE-A151804
A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
Protocol No
BERGENBIO-BGB324
Sub Category
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies
Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility
Protocol No
ADP-0000-001-SCR
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance in Small Cell Lung Cancer
Protocol No
NRG-CC003
Sub Category
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
Sitravatinib + Nivolumab vs Docetaxel in Patients with Advanced Non-Squamous NSCLC
Protocol No
MIRATI-516-005
Sub Category
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Targeted Treatment for Advanced Non-Small Cell Lung Cancer
Protocol No
SWOG-LUNGMAP
Sub Category
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Protocol No
ALLIANCE-ALCHEMIST-A151216
Sub Category